IBCSG 53-14 PYTHIA

  • A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2-Metastatic Breast Cancer.

    Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer: the PYTHIA study.

  • Study Chair
    Dr. Luca Malorni (Prato, Italy)

    Statistician
    Meredith Regan, ScD

    Trial Coordinator
    Poonam Jani

    Data Manager
    Adriana Mora de Karausch, Monica Greco

    IBCSG Data Management Center/Frontier Science Foundation
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Monitoring 
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

    Date of Activation
    August 28, 2015

    Targeted Accrual
    122

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login